No Patient or Illness to be Treated?: The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca)

Hans Vedder

doi:10.1093/jeclap/lpv057

No Patient or Illness to be Treated? The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca)

Hans Vedder

Research output: Contribution to journal › Article › Academic › peer-review

72 Downloads (Pure)

Abstract

This article discusses the decision of the netherlands competition authority in the AstraZeneca case and puts this in a broader perspective of regulation in the pharmaceutical market, price regulation and responses to market failures.

Original language	English
Pages (from-to)	664-668
Number of pages	5
Journal	Journal of European Competition Law & Practice
Volume	6
Issue number	9
Early online date	25-Aug-2015
DOIs	https://doi.org/10.1093/jeclap/lpv057
Publication status	Published - 2015

Keywords

Pharmaceutical markets
competition law

Access to Document

10.1093/jeclap/lpv057

Journal_of_European_Competition_Law_Practice_2015_Vedder_jeclap_lpv057Final publisher's version, 73.5 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{759bdcaf14094943bfee4292e48101ba,

title = "No Patient or Illness to be Treated?: The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca)",

abstract = "This article discusses the decision of the netherlands competition authority in the AstraZeneca case and puts this in a broader perspective of regulation in the pharmaceutical market, price regulation and responses to market failures.",

keywords = "Pharmaceutical markets, competition law",

author = "Hans Vedder",

year = "2015",

doi = "10.1093/jeclap/lpv057",

language = "English",

volume = "6",

pages = "664--668",

journal = "Journal of European Competition Law \& Practice",

issn = "2041-7764",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - No Patient or Illness to be Treated?

T2 - The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca)

AU - Vedder, Hans

PY - 2015

Y1 - 2015

N2 - This article discusses the decision of the netherlands competition authority in the AstraZeneca case and puts this in a broader perspective of regulation in the pharmaceutical market, price regulation and responses to market failures.

AB - This article discusses the decision of the netherlands competition authority in the AstraZeneca case and puts this in a broader perspective of regulation in the pharmaceutical market, price regulation and responses to market failures.

KW - Pharmaceutical markets

KW - competition law

U2 - 10.1093/jeclap/lpv057

DO - 10.1093/jeclap/lpv057

M3 - Article

SN - 2041-7764

VL - 6

SP - 664

EP - 668

JO - Journal of European Competition Law & Practice

JF - Journal of European Competition Law & Practice

IS - 9

ER -